Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus DICYCLOMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus DICYCLOMINE HYDROCHLORIDE.
BENTYL vs DICYCLOMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
10-20 mg orally 3-4 times daily
None Documented
None Documented
1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Category C
Category A/B
Anticholinergic
Anticholinergic